SHAILYNSE13 May 2025

Shaily Engineering Plastics Limited has informed the Exchange about Investor Presentation

Shaily Engineering Plastics Limited

SEPL/SE/May/25-26 13th May 2025

The General Manager, Corporate Relations/Listing Department BSE Limited Floor 25, P.J. Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 501423

The Manager, Listing Department National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra – Kurla Complex, Bandra (E), Mumbai – 400 051 Scrip Code: SHAILY

Sub: Q4 & FY25 – Investor Presentation

Ref:

Regulation 30 of the SEBI Listing Regulations, 2015

Dear Sir,

In continuation to our letter dated 08th May 2025, regarding intimation of Earnings Call of the Company scheduled on Wednesday, 14th May 2025 at 10:00 a.m., IST, to discuss the operational & financial performance of the Company for the quarter ended on 31st March 2025, kindly find enclosed herewith Q4 & FY25 Investor Presentation of the Company.

A copy of the same is also available on our website www.shaily.com.

Kindly take the same on record.

Thanking You.

Yours truly, For Shaily Engineering Plastics Limited

Harish Punwani Company Secretary & Compliance Officer M. No. A 50950

Encl: a/a

Shaily Engineering Plastics Ltd

Investors Presentation May 2025

Safe Harbor

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Shaily Engineering Plastics Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

Key Performance Highlights

Business Updates for FY25

Healthcare

Consumer

Industrial

✓ Commercial Supplies of pens for GLP-1 drug ‘Semaglutide’ will

start in FY26

✓ 2 new customers added for IP led pen platforms signed in Q4

FY25

✓ Pen manufacturing capacity is being expanded in FY26

✓ Successfully participated in Pharma Pack 2025, Paris:

Participation in Pharma Pack exhibition in Paris to showcase our innovations in medical device space

✓ Signed 6 contracts for Pen Injectors: Signed 6 contracts with

different customers for Pen Injectors for GLP 1 / Other therapies

✓ Successfully participated in Global Drug exhibition: Participation in Global Drug Exhibitions across Europe & USA to showcase IP Led pen platforms

✓ 2 new products added in plastics and 3 new

products added in carbon steel with home furnishing customer in Q4 FY25

✓ New Product added with FMCG customer in Q4

FY25

✓ New Business awarded from 2 global retail chains to start from Q1/Q2 FY26 – Supplies started

✓ New Business received for 2 new products with

marque FMCG Customer

✓ Business awarded for 2 new products under

development

✓ Successfully participated in Cosmoprof, Mumbai:

Participation in Cosmoprof exhibition in Mumbai to showcase our speciality packaging expertise

✓ New Business Confirmation: Business awarded from new marquee customer for automotive components in Q4 FY25

✓ New Business Confirmation: New

business confirmed for supply of knobs for export

✓ New Business Confirmation: Business awarded from new marquee customer for automotive components in Q2 FY25

Continued Growth Momentum across FY25 (Consolidated*)

Revenues

Gross Profit & GP Margins

42.1%

46.3%

47.5%

51.7%

+7%

+3%

179.4

192.0

197.6

+10%

217.8

+18%

+6%

89.0

93.9

75.5

+20%

112.6

Q1FY25

Q2FY25

Q3FY25

Q4FY25

Q1FY25

Q2FY25

Q3FY25

Q4FY25

Highest ever Revenues & Profitability recorded in FY25 This has been on the back of improved traction seen across segments and ramp up in projects. The visibility we have across various businesses gives immense confidence that we will be able to scale up further and grow

(Rs. Cr.)

* Includes the UK Subsidiary Business

Continued Growth Momentum across FY25 (Consolidated*)

EBITDA & EBITDA Margins

Profit After Tax & PAT Margins

20.1%

21.5%

23.4%

25.1%

9.7%

11.4%

12.8%

13.1%

+14%

41.3

36.1

+12%

46.3

+18%

54.6

+26%

21.9

+15%

25.2

17.4

+13%

28.6

Q1FY25

Q2FY25

Q3FY25

Q4FY25

Q1FY25

Q2FY25

Q3FY25

Q4FY25

(Rs. Cr.)

* Includes the UK Subsidiary Business

Segment Wise Revenue Breakup

Consumer Segment

Healthcare Segment

+4%

+2%

+5%

132.8

138.6

141.3

148.1

+36%

+17%

37.4

43.7

27.4

+28%

56.0

Q1FY25

Q2FY25

Q3FY25

Q4FY25

Q1FY25

Q2FY25

Q3FY25

Q4FY25

Industrial Segment

Total Revenue

-16%

19.2

16.0

-22%

+9%

12.5

13.7

+7%

+3%

179.4

192.0

197.6

+10%

217.8

Q1FY25

Q2FY25

Q3FY25

Q4FY25

Q1FY25

Q2FY25

Q3FY25

Q4FY25

(Rs. Cr.)

On Consolidated Basis

Key Financial Highlights – Q4 & FY25 (Consolidated*)

Revenues

Gross Profit Margin

EBITDA

+28%

217.8

170.6

+22%

786.8

643.9

+490 bps

+470 bps

46.8%

51.7%

42.5%

47.2%

+51%

54.6

+45%

178.4

36.3

123.4

Q4FY24 Q4FY25

FY24

FY25

Q4FY24 Q4FY25

FY24

FY25

Q4FY24 Q4FY25

FY24

FY25

EBITDA Margins

Profit After Tax

Cash PAT#

+380 bps

+350 bps

25.1%

21.3%

22.7%

19.2%

+48%

28.6

+63%

93.1

19.3

57.3

+35%

39.7

29.3

+45%

135.3

93.0

Q4FY24 Q4FY25

FY24

FY25

Q4FY24 Q4FY25

FY24

FY25

Q4FY24 Q4FY25

FY24

FY25

(Rs. Cr.)

#Cash PAT includes PAT & Depreciation

* Includes the UK Subsidiary Business

Segment Wise Revenue Breakup

Revenue (Consumer)

Revenue (Healthcare)

Revenue (Industrial)

TOTAL REVENUE

+27%

148.1

5 2 Y F 4 Q

116.7

+45%

38.6

56.0

15.2

-10%

13.7

+28%

217.8

170.6

Q4FY24

Q4FY25

Q4FY24

Q4FY25

Q4FY24

Q4FY25

Q4FY24

Q4FY25

Revenue (Consumer)

Revenue (Healthcare)

Revenue (Industrial)

TOTAL REVENUE

+17%

560.8

5 2 Y F

481.2

+53%

164.7

107.7

+12%

55.0

61.4

+22%

786.8

643.9

FY24

FY25

FY24

FY25

FY24

FY25

FY24

FY25

On Consolidated Basis

Key Financial Highlights – Q4 & FY25 (Standalone)

Revenues

Gross Profit Margin

EBITDA

+25%

203.3

162.8

+20%

738.1

616.0

+410 bps

+380 bps

44.2%

48.3%

39.9%

43.7%

+76%

52.4

29.8

+49%

151.0

101.3

Q4FY24 Q4FY25

FY24

FY25

Q4FY24 Q4FY25

FY24

FY25

Q4FY24 Q4FY25

FY24

FY25

EBITDA Margins

Profit After Tax

Cash PAT#

+750 bps

+410 bps

25.8%

20.5%

16.4%

18.3%

+159%

29.5

+96%

70.9

+91%

39.9

11.4

36.1

20.8

+56%

110.3

70.8

Q4FY24 Q4FY25

FY24

FY25

Q4FY24 Q4FY25

FY24

FY25

Q4FY24 Q4FY25

FY24

FY25

(Rs. Cr.)

#Cash PAT includes PAT & Depreciation

Operational Trends

n o i t a z i l i t U e n h c a M

)

(

s t n a P s s o r c A

+416 bps

+210 bps

39.8%

44.0%

40.1%

42.2%

Revenue Analysis – Domestic vs. Exports

Q4 FY24

Q4 FY25

Q4FY24

Q4FY25

FY24

FY25

73.1%

79.9%

26.9%

20.1%

s r e m y l o P f o e m u o V

) T M

( d e s s e c o r P

+21%

6,536

5,380

+13%

24,932

22,098

Q4FY24

Q4FY25

FY24

FY25

FY24

FY25

26.1%

22.2%

73.9%

77.8%

Efficient Use of Capital

RoCE

RoE

Fixed Asset Turnover

Total Debt / Equity

+670 bps

24.4%

+520 bps

18.5%

1.71

0.5

1.48

17.7%

13.3%

0.4

Mar-24

Mar-25

Mar-24

Mar-25

Mar-24

Mar-25

Mar-24

Mar-25

On Consolidated Basis

Profit & Loss Statement

Consolidated

Standalone

Particulars (Rs. Cr.)

Q4 FY25

Q4 FY24

YoY %

170.6

28%

Q4 FY25

Q4 FY24

YoY %

162.8

25%

Revenue

Raw Material

Employee Expenses

Other Expenses*

Other Income

EBITDA

217.8

105.2

23.2

34.9

0.1

54.6

90.8

15.8

29.3

1.6

36.3

EBITDA Margin

25.1%

21.3%

Depreciation

Finance Cost

PBT

PBT Margin

Tax

PAT

PAT Margin

Cash PAT^

Cash PAT Margin

11.1

3.9

39.6

10.0

4.7

21.6

18.2%

12.6%

11.0

28.6

13.1%

39.7

18.2%

2.2

19.3

11.3%

29.3

17.2%

51%

84%

48%

35%

FY25

786.8

415.8

80.4

114.5

2.3

178.4

22.7%

42.2

16.9

119.3

15.2%

26.2

93.1

11.8%

135.3

17.2%

FY24

643.9

370.1

57.3

99.5

6.5

123.4

19.2%

35.7

17.9

69.8

10.8%

12.6

57.3

8.9%

93.0

14.4%

YoY %

22%

45%

71%

63%

45%

203.3

105.2

19.7

30.5

4.5

52.4

90.8

15.0

28.7

1.6

29.8

25.8%

18.3%

10.4

3.9

38.1

18.8%

8.6

29.5

14.5%

39.9

19.6%

9.5

4.7

15.7

9.6%

4.3

11.4

7.0%

20.8

12.8%

76%

143%

159%

91%

* Other Expenses include Power & Fuel costs

^ Cash PAT = PAT + Depreciation

FY25

738.1

415.7

72.8

106.0

7.4

151.0

20.5%

39.4

16.9

94.7

12.8%

23.7

70.9

9.6%

110.3

14.9%

FY24

616.0

370.1

55.9

95.2

6.5

101.3

16.4%

34.7

17.9

48.7

7.9%

12.6

36.1

5.9%

70.8

11.5%

YoY %

20%

49%

94%

96%

56%

Balance Sheet

Particulars (Rs. Crs.) Non-Current assets Property, Plant and Equipments Capital Work in Process Intangible assets Investments Intangible assets under development Financial Assets Loans Other Non-Current Assets Income tax assets Total Non-Current Assets Current Assets Inventories Financial Assets Trade Receivables Cash and Cash Equivalents Loans Other Current Assets Current tax assets (Net) Total Current Assets Total Assets

Mar-25

Mar-24

459.1 17.4 42.1 - 0.3

0.5 23.9 3.8 547.0

435.4 15.3 38.0 - 5.1

0.5 18.3 2.7 515.3

137.8

83.6

171.7 23.1 0.3 52.6 - 385.6 932.6

117.4 26.4 6.4 33.5 - 267.2 782.5

Particulars (Rs. Crs.) Equity Equity Share Capital Other Equity

Total Equity Non-Current Liabilities Financial Liabilities Long-term borrowings Deferred tax liabilities (net) Other long-term liabilities Long-term provisions

Total Non-Current Liabilities Current Liabilities Short-term borrowings Trade payables Other financial liabilities Other current liabilities Short-term provisions Current tax liabilities (net) Total Current Liabilities

Total Equity and Liabilities

Mar-25

Mar-24

9.2 538.5

547.7

40.1 23.6 0.2 3.9

67.8

147.6 99.0 12.5 44.0 7.1 6.9 317.1

932.6

9.2 450.0

459.2

69.8 20.8 1.2 2.2

94.1

138.5 68.7 10.3 10.4 1.3 0.0 229.2

782.5

On Consolidated basis

Balance Sheet

Particulars Non-Current assets Property, Plant and Equipments Capital Work in Process Intangible assets Investments Intangible assets under development Financial Assets Loans Other Non-Current Assets Income tax assets Total Non-Current Assets Current Assets Inventories Financial Assets Trade Receivables Cash and Cash Equivalents Loans Other Current Assets Current tax assets (Net) Total Current Assets Total Assets

Mar-25

Mar-24

457.6 17.4 19.5 11.3 0.3

0.5 23.9 1.5 532.0

434.9 15.3 17.8 20.6 2.1

0.5 18.3 2.3 511.8

137.8

83.6

148.1 8.5 0.3 44.0 - 338.7 870.6

111.7 8.6 6.4 29.9 - 240.3 752.1

Particulars Equity Equity Share Capital Other Equity

Total Equity Non-Current Liabilities Financial Liabilities Long-term borrowings Deferred tax liabilities (net) Other long-term liabilities Long-term provisions

Total Equity and Liabilities

Mar-25

Mar-24

9.2 487.0

496.2

40.1 22.6 0.2 3.9

66.8

147.6 97.9 12.5 38.0 7.1 4.4 307.6

870.6

9.2 422.3

431.5

69.8 20.4 1.2 2.2

93.6

138.5 67.2 10.3 9.7 1.3 - 227.0

752.1

On Standalone basis

Cash Flow Statement

Particulars (Rs. Cr.)

Profit Before Tax

Adjustments

Operating profit before working capital changes

Changes in working capital

Cash generated from operations

Direct taxes paid (net of refund)

Net Cash from Operating Activities

Net Cash from Investing Activities

Net Cash from Financing Activities

Net Change in cash and cash equivalents

Add: Cash & Cash equivalents at the beginning of the period

Closing Cash Balance

On Consolidated basis

Consolidated

Standalone

FY25

119.3

56.6

175.9

-48.3

127.6

-17.5

110.1

-71.3

-41.9

-3.1

22.2

19.1

FY24

69.8

58.2

128.0

-27.0

101.0

-8.8

92.3

-99.0

9.8

3.1

19.1

22.2

FY25

94.7

46.6

141.3

-30.5

110.7

-15.1

95.6

-53.7

-41.9

0.0

4.4

FY24

48.7

56.2

104.8

-21.6

83.3

-8.8

74.5

-92.4

4.6

-13.3

17.7

4.4

About the Company

Enriching Lives Through Plastics

Shaily Engineering Plastics Limited is India’s largest exporter of plastics components. Established in 1987, the Company provides end-to-end solutions in plastic products and services, whilst delivering superior quality and value to all stakeholders. The Company employs over 2,000+ employees and have over 200+ injection molding machines, with precise, high speed automated and robotic production lines.

Founded in 1987

Revenue* Rs. 787 Crores FY 25

7 Facilities in Gujarat 6 for Plastic 1 for Steel Furniture

Long-standing global relationships with marquee clients

200+ Injection moulding machines

Over 2,000 employees across 7 plants

De-risked Business Model

On Consolidated Basis

Business Segments

Consumer

Industrial

Healthcare

✓ Home Furnishings

✓ FMCG Packaging

✓ LED Lights

✓ Toys

✓ Carbon Steel Furniture

✓ Automotive Components

✓ Appliances

✓ High Performance Engineering Components

✓ Platform Devices

✓ Drug Delivery Devices

✓ Pharma Packaging

State-of-the-Art Manufacturing Facilities

7 Facilities with over 200 molding machines ranging from 35 tons to 1,000 tons

Rania

Halol

GUJARAT

Rania

❖ Export Oriented Unit ❖ Pharma (Dedicated ISO Class 8 clean

room manufacturing facility)

❖ Others

Halol (GIDC)

❖ Automotive & Engineering

Halol

❖ Carbon Steel ❖ Plastic

Disclaimer: Maps not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Board of Directors

Executive Chairman

Mr. Mahendra Sanghvi

Whole Time Director

Ms. Tilottama Sanghvi

Managing Director

Mr. Amit Sanghvi

Executive Director

Mr. Laxman Sanghvi

Independent Director

Dr. Shailesh Ayyangar

Independent Director

Mr. Ranjit Singh

Independent Director

Mr. Samaresh Parida

Independent Director

Mrs. Sangeeta Singh

Strong Credit Rating*

LONG TERM BANK FACILITIES

Rs. 238.45 Crs.

CARE A+ ; Outlook: Stable

Rating Action: Upgraded

SHORT TERM BANK FACILITIES

Rs. 35 Crs.

CARE A1

Rating Action: Reaffirmed

Long and established track record in the plastic injection molding business along with experienced Promoters

Growth in Total operating income on the back of increased volumes & higher exports

Sustainable healthy operating margin along with strengthening leverage and debt coverage indicators

New business confirmations from existing clients along with addition of marquee clients across diversified industries

Sustainable healthy operating margin along with strengthening leverage and debt coverage indicators

*Updated as on 31st March 2025

Historical Profit & Loss Statement

Particulars (Rs. Cr.)

Revenue

Raw Material

Employee Expenses

Other Expenses*

Other Income

EBITDA

EBITDA Margin

Depreciation

Finance Cost

PBT

PBT Margin

Tax

PAT

PAT Margin

Cash PAT^

Cash PAT Margin

Consolidated

Standalone

FY25

786.8

415.8

80.4

114.5

2.3

178.4

22.7%

42.2

16.9

119.3

15.2%

26.2

93.1

11.8%

135.3

17.2%

FY24

643.9

370.1

57.3

99.5

6.5

123.4

19.2%

35.7

17.9

69.8

10.8%

12.6

57.3

8.9%

93.0

14.4%

FY23

607.1

386.5

47.9

80.8

4.5

96.4

15.9%

33.3

17.9

45.2

7.4%

10.1

35.1

5.8%

68.5

11.3%

FY25

738.1

415.7

72.8

106.0

7.4

151.0

20.5%

39.4

16.9

94.7

12.8%

23.7

70.9

9.6%

110.3

14.9%

FY24

616.0

370.1

55.9

95.2

6.5

101.3

16.4%

34.7

17.9

48.7

7.9%

12.6

36.1

5.9%

70.8

FY23

599.7

386.5

47.2

79.4

4.5

91.1

15.2%

33.2

17.9

40.1

6.7%

10.1

30.0

5.0%

63.2

11.5%

10.5%

* Other Expenses include Power & Fuel costs

^ Cash PAT = PAT + Depreciation

Historical Balance Sheet

Mar-25

Mar-24

Mar-23

459.1 17.4 42.1 - 0.3

0.5 23.9 3.8 547.0

435.4 15.3 38.0 0.0 5.1

0.5 18.3 2.7 515.3

347.9 49.0 19.0 0.0 19.3

0.5 17.2 2.1 455.0

137.8

83.6

73.0

171.7 23.1 0.3 52.6 - 385.6 932.6

117.4 26.4 6.4 33.5 0.0 267.2 782.5

91.9 23.0 5.7 44.1 0.0 237.7 692.7

Particulars Equity Equity Share Capital Other Equity

Total Equity Non-Current Liabilities Financial Liabilities Long-term borrowings Deferred tax liabilities (net) Other long-term liabilities Long-term provisions

Total Equity and Liabilities

Mar-25

Mar-24

Mar-23

9.2 538.5

547.7

40.1 23.6 0.2 3.9

67.8

147.6 99.0 12.5 44.0 7.1 6.9 317.1

932.6

9.2 450.0

459.2

69.8 20.8 1.2 2.2

94.1

138.5 68.7 10.3 10.4 1.3 0.0 229.2

782.5

9.2 392.2

401.4

62.5 17.0 1.2 2.3

83.1

124.3 53.4 9.3 20.0 1.2 0.0 208.2

692.7

On Consolidated basis

Historical Balance Sheet

Mar-25

Mar-24

Mar-23

457.6 17.4 19.5 11.3 0.3

0.5 23.9 1.5 532.0

434.9 15.3 17.8 20.6 2.1

0.5 18.3 2.3 511.8

348.6 49.0 13.8 15.4 5.7

0.5 17.2 2.1 452.3

137.8

83.6

73.0

148.1 8.5 0.3 44.0 - 338.7 870.6

111.7 8.6 6.4 29.9 0.0 240.3 752.1

88.8 17.7 13.7 39.2 0.0 232.4 684.6

Particulars Equity Equity Share Capital Other Equity

Total Equity Non-Current Liabilities Financial Liabilities Long-term borrowings Deferred tax liabilities (net) Other long-term liabilities Long-term provisions

Total Equity and Liabilities

Mar-25

Mar-24

Mar-23

9.2 487.0

496.2

40.1 22.6 0.2 3.9

66.8

147.6 97.9 12.5 38.0 7.1 4.4 307.6

870.6

9.2 422.3

431.5

69.8 20.4 1.2 2.2

93.6

138.5 67.2 10.3 9.7 1.3 0.0 227.0

752.1

9.2 386.5

395.6

62.5 16.9 1.2 2.3

82.9

123.2 51.7 10.4 19.5 1.2 0.0 206.1

684.6

On Standalone basis

Cash Flow Statement

Consolidated

Standalone

Particulars (Rs. Cr.)

Profit Before Tax

Adjustments

Operating profit before working capital changes

Changes in working capital

Cash generated from operations

Direct taxes paid (net of refund)

Net Cash from Operating Activities

Net Cash from Investing Activities

Net Cash from Financing Activities

Net Change in cash and cash equivalents

Add: Cash & Cash equivalents at the beginning of the period

Closing Cash Balance

FY25

119.3

56.6

175.9

-48.3

127.6

-17.5

110.1

-71.3

-41.9

-3.1

22.2

19.1

FY24

69.8

58.2

128.0

-27.0

101.0

-8.8

92.3

-99.0

9.8

3.1

19.1

22.2

FY23

45.2

51.4

96.6

-0.6

96.0

-6.0

90.0

-100.9

-5.1

-16.0

35.1

19.1

FY25

94.7

46.6

141.3

-30.5

110.7

-15.1

95.6

-53.7

-41.9

0.0

4.4

FY24

48.7

56.2

104.8

-21.6

83.3

-8.8

74.5

-92.4

4.6

-13.3

17.7

4.4

FY23

40.1

50.4

90.5

0.2

90.7

-6.0

84.7

-93.3

-5.1

-13.7

31.4

17.7

Contact

Company :

Investor Relations Advisors :

Shaily Engineering Plastics Ltd. CIN – L51900GJ1980PLC065554

Mr. Sanjay Shah, Chief Strategy Officer sanjay@shaily.com

www.shaily.com

Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Deven Dhruva shogun.jain@sgapl.net / deven.dhruva@sgapl.net +91 77383 77756 / +91 98333 73300 www.sgapl.net

← All Transcripts SHAILY Stock Page →

Shaily Engineering Plastics Limited has informed the Exchange about Investor Presentation

Market Movers